Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.49
+3.22 (1.57%)
AAPL  272.09
+5.91 (2.22%)
AMD  214.08
+17.48 (8.89%)
BAC  50.30
-0.77 (-1.52%)
GOOG  311.16
-0.53 (-0.17%)
META  638.24
+0.99 (0.16%)
MSFT  388.53
+4.06 (1.06%)
NVDA  193.53
+1.98 (1.03%)
ORCL  145.81
+4.50 (3.18%)
TSLA  410.69
+10.86 (2.72%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.